Response to Feuerstein J et al. “Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005–2013) for Barrett’s Esophagus”. doi:10.1007/s10620-016-4222-2-Reference-Cited by-同舟云学术

Response to Feuerstein J et al. “Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005–2013) for Barrett’s Esophagus”. doi:10.1007/s10620-016-4222-2

Published:2016-09-22 Issue:11 Volume:61 Page:3369-3371
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Bennett Cathy^ORCID, ,Jankowski Janusz,Moayyedi Paul

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://link.springer.com/content/pdf/10.1007/s10620-016-4279-y.pdf

Reference9 articles.

1. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143:336–346.

2. Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol. 2015;110:662–682 (quiz 683).

3. National Institute for Health and Clinical Excellence (NICE). Final Accreditation Report: Consensus Statements for Management of Barrett’s Dysplasia and Early-Stage Oesophageal Adenocarcinoma. 2012. https://www.nice.org.uk/Media/Default/About/accreditation/accreditation-decisions/BAD-CAT-consensus-group-final-decision.pdf . Accessed July 5, 2016.

4. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–394.

5. Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161–169.